BP control in diabetic patients is often poor. The contribution of secondary hypertension due to undiagnosed PA in hypertensive type 2 diabetic patients is not well studied. We prospectively screened 100 consecutive Asian type 2 diabetic patients with difficult-to-control or resistant hypertension for PA. PAC (pmol/L) to PRA (ng/mL/h) ratio was measured; those with PAC-to-PRA ratio >550 (corresponding PAC >415) underwent intravenous 0.9% SLT. Patients with PAC ≥140 following SLT had CT adrenals and bilateral AVS. Thirteen patients (13%) were confirmed to have PA, and all had resistant hypertension. Eight had a surgically correctable form of PA. Patients with PA had higher mean (SD) systolic 
Introduction
CVD is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus. 1 Hypertension, one of the major independent risk factors for CVD, is more prevalent amongst diabetics. 2, 3 Tight BP control in type 2 diabetic patients not only significantly reduces the incidence of microvascular complications, but also reduces the incidence of cardiovascular complications such as heart failure and stroke. 4 However, despite this compelling evidence, the number of diabetics who achieve target BP is dismal, with approximately 50-75% failing to achieve good BP control. 5, 6 Diabetic nephropathy, hyperinsulinaemia 7 and extracellular volume expansion 8 have been proposed to contribute to hypertension in diabetic patients. However, the contribution of excess aldosterone in the pathogenesis of hypertension in patients with type 2 diabetes mellitus remains unknown. Aldosterone is principally involved in the maintenance of sodium and water homeostasis. Excess aldosterone, as seen in patients with PA, leads to excess sodium and water retention, and eventual hypertension. PA is now recognised as the commonest cause of secondary hypertension. 9 Importantly, early diagnosis and treatment of PA offers a potential cure for hypertension. decreases baroreflex sensitivity and enhances sympathetic activity, 15 abnormalities that might contribute to hypertension in diabetes mellitus. Indeed, the prevalence of cardiovascular events is greater in patients with PA than in those with essential hypertension, 16 further suggesting a pathological role of excess aldosterone in CVD, independent of BP.
There is accumulating evidence to suggest a close relationship between aldosterone excess and insulin resistance. Aldosterone promotes insulin resistance via defects in insulin signalling and glucose uptake in the skeletal tissue. 17, 18 A high prevalence of glucose intolerance and/or diabetes mellitus has also been reported in patients with PA. 19, 20 On the other hand, hyperinsulinaemia, a feature of insulin resistance, is known to stimulate the production of aldosterone. 21, 22 Since patients with diabetes mellitus and hypertension are typically insulin-resistant, it has been postulated that excess aldosterone may contribute to poorly controlled hypertension in patients with diabetes mellitus. 18 It is thus probable that the prevalence of PA might be higher in hypertensive type 2 diabetic patients.
The primary aim of our study was to examine the prevalence of PA in diabetic patients with poorly controlled hypertension in the Asian context. To date, there is only one published study that suggests a high prevalence of PA amongst diabetic patients with resistant hypertension. 23 Early diagnosis and treatment of PA might reduce the burden of CVD in type 2 diabetic patients.
Research design and methods
This study aimed to screen for PA in adult diabetic patients with poorly controlled hypertension. We enrolled 100 consecutive type 2 diabetic patients with difficult-to-control or resistant hypertension. The patients were recruited from those attending the Diabetes Centre at the National University Hospital, Singapore, over a period of one year from July 2004 to June 2005. Exclusion criteria included the presence of elevated serum creatinine value greater than 160 µmol/L, pregnancy or breast-feeding, history of congestive cardiac failure, known pheochromocytoma or Cushing's syndrome. All patients were on stable antihypertensive medications for at least four weeks before evaluation. None of these patients were on treatment with either Spironolactone or Epleronone. The study was approved by the local ethics committee.
Following written informed consent, all patients gave a detailed history and underwent physical examination and anthropometric measurements. BP was measured using a mercury sphygmomanometer with the patient sitting, after 15 min of rest. In the event that BP was >140/90 mmHg, repeat measurements were taken using a sphygmomanometer with the patient sitting on two further occasions, 5 min apart, and the average of the last two readings was used for data analysis.
As described by Moser and Setaro, 24 difficult-to-control hypertension was defined as BP >140/90 mmHg despite taking two different classes of antihypertensive medications for at least three months or requiring three or more different classes of antihypertensive medications for BP control. Resistant hypertension was defined as BP >140/90 mmHg despite adherence to optimum treatment with three or more different classes of antihypertensive medications.
Screening and diagnosis of PA
Fasting blood samples were drawn in the morning, with the patient in a sitting position, after having rested for 30 min. Blood was collected for measurement of serum potassium, serum creatinine, HbA 1C , PAC (pmol/L) and PRA (ng/mL/h).
PAC-to-PRA ratio was calculated in all patients. Patients with a positive screening test, defined as PAC-to-PRA ratio >550 (with a corresponding PAC value >415 pmol/L), underwent a confirmatory 4-h intravenous 0.9% SLT. During this test, PAC was measured 4 h after the intravenous administration of 2 litres of 0.9% saline at the rate of 500 mL/h. Patients with a PAC value ≥140 pmol/L following SLT (post-PAC) underwent further investigations, including CT with fine cuts (3 mm) of the adrenals, and bilateral AVS for PAC, to determine the aetiology of PA. Adrenal vein cannulation was considered successful if the adrenal vein/inferior vena cava cortisol gradient was at least two, and was considered to show lateralisation when the aldosterone/cortisol ratio in one adrenal vein was at least four times the ratio in the other adrenal vein. 25 
Laboratory measurements
All hormonal assays were performed in the biochemistry laboratory at the National University Hospital, Singapore, which is accredited by the College of American Pathologists. PAC was measured using a solid-phase 125-I RIA (Siemens Medical Solutions Diagnostics, LA, USA); the intra-assay and inter-assay CV for PAC were 3.4% and 6.5%, respectively. PRA was measured by quantifying angiotensin I, generated after incubation of plasma, by standard RIA (DiaSorin, Stillater, MN, USA); the intra-assay and interassay CV for PRA were 4.6% and 7.6%, respectively. The reference ranges for upright PAC and PRA were 110-860 pmol/L and 1.31-3.95 ng/mL/h respectively. HbA 1C was measured using an ion exchange chromatography method (Variant II, Bio-Rad Laboratories).
Statistical analysis
All values are expressed as means ± SD unless otherwise noted. Comparisons of continuous variables between patients with and without PA were carried out using Student t test. A two-tailed p <0.05 was considered significant.
Statistical analysis was performed with SPSS (version 13.0 for Windows; SPSS Inc., Chicago, IL).
Results

Clinical characteristics of 100 hypertensive type 2 diabetic patients (tables 1 and 2)
The baseline clinical characteristics of all 100 type 2 diabetic patients are shown in tables 1 and 2. The study patients had a mean (SD) age of 57.4 (9.7) years, and 46% were male. The mean (SD) duration of diabetes and hypertension were 11.4 (7.8) and 12.8 (8.6) years respectively. Fifty-two patients had difficult-to-control hypertension and 48 had resistant hypertension. The mean (SD) systolic and diastolic BP were 147.8 (11.6) and 88.5 (6.4) mmHg respectively. Thirteen patients (13%) were confirmed to have PA, and all of them had resistant hypertension.
Clinical characteristics of the 13 patients with confirmed PA (table 1)
There was no difference in age, BMI, duration of diabetes or hypertension, HbA 1C , and number of antihypertensive medications used between the patients with and without PA. Patients with PA had higher mean systolic and diastolic BP but lower mean serum potassium than patients without PA. Serum potassium was measured in all patients during the initial screening visit when none were on potassium supplements. Six (46%) patients had a screening serum potassium value lower than 3.5 mmol/L.
The patients with PA had higher mean PAC (679.3 vs. 239.5 pmol/L, p<0.001), lower PRA (0.34 vs. 4.91 ng/mL/h, p<0.001), and higher PAC-to-PRA ratio (2,315.8 vs. 345.0, p<0.001) when compared with those without PA.
Subtype differentiation amongst 13 patients with PA (table 2)
Of the 13 patients with confirmed PA, eight had a surgically correctable form of PA: seven had a unilateral APA and one had primary adrenal hyperplasia. Of the remaining five patients, four had BAH, and in one the aetiology remained indeterminate.
Of the seven patients with confirmed APA, six had a unilateral adrenal adenoma visible on CT scan (size ranging from 1.0 cm to 2.6 cm), and one had bilateral adrenal nodules (2.6 cm in the left, and 0.6 cm in the Key: Data are expressed as mean ± SD unless stated otherwise. ACE = angiotensin converting enzyme; AHT = antihypertensive medication; ARB = angiotensin receptor blocker; BMI = body mass index; BP = blood pressure; DM = diabetes mellitus; HbA 1C = glycosylated haemoglobin; HTN = hypertension; NS = non-significant; PA = primary aldosteronism; PAC = plasma aldosterone concentration; PRA = plasma renin activity; SD = standard deviation right adrenal gland). Six of the seven patients with APA underwent AVS, which lateralised the source of aldosterone secretion to the side of the visible adenoma in the five with unilateral adenoma, and to the left side in the patient with bilateral adrenal nodules. Five patients have undergone unilateral adrenalectomy; histology confirmed an adrenal adenoma. Post-adrenalectomy, all five had normalisation of previously noted low serum potassium values that had earlier necessitated potassium replacement, together with improvement in hypertension control, with not only fewer, but also reduced dosages of, antihypertensive medications. The other two patients with APA (one with poor cardiac function, and another, a 65-year-old woman, with a visible 1.3 cm adenoma on the left adrenal gland, who refused surgery) are on spironolactone with good BP control. One patient with PA, a 69-year-old man, had a hyperplastic right adrenal gland with a 0.8 cm nodule visible within this gland on CT scan. The left adrenal gland was normal. AVS lateralised the source of excess aldosterone secretion to the right side. He underwent right adrenalectomy. Histology revealed an adrenal gland with small focal areas of cortical hyperplasia with a few small cortical nodules, the largest measuring 2 mm in diameter. No definite adenoma was identified, a finding consistent with primary adrenal hyperplasia. Similar to the response seen in the five patients with APA treated surgically, following unilateral laparoscopic adrenalectomy, there was normalisation of previously noted low serum potassium values in this patient, together with improvement in his BP control.
All four patients with BAH had hyperplastic adrenal glands on CT scan. AVS failed to lateralise the source of aldosterone secretion in all four patients. They were treated with spironolactone, with good BP control.
The subtype of the last patient with confirmed PA remained indeterminate. Although both adrenal glands appeared hyperplastic on CT scan, AVS lateralised the source of aldosterone secretion to the right side. However, in the absence of a visible nodule on imaging, the patient refused adrenalectomy, and preferred follow-up whilst on spironolactone for BP control.
Discussion
Diabetes mellitus and hypertension constitute two powerful independent risk factors for cardiovascular, renal and atherosclerotic disease. 26, 27 Better control of hypertension in diabetic patients is crucial in order to reduce the risk of cardiovascular morbidity and mortality. 4 The benefits of tight BP control in diabetic patients were conclusively demonstrated by the UKPDS, 28 and fur ther reinforced by the findings in the HOT trial, which revealed that a 4 mmHg reduction in diastolic BP led to an impressive 51% risk reduction in CVD. 29 Despite this compelling evidence, only a minority of diabetic patients achieve target BP of 130/80 mmHg. 5 Poor patient compliance, cost and side effects of antihypertensive medications, presence of co-morbidities, and physicians' lack of adherence to practice guidelines for managing hypertension are often cited as the principal reasons for poorly controlled hypertension in diabetic patients. 30 The contribution of undiagnosed PA to the failure to achieve good BP control in type 2 diabetic patients is relatively unknown. Key: Data are expressed as mean ± SD unless stated otherwise. APA = aldosterone-producing adenoma; AVS = adrenal venous sampling; BAH = bilateral adrenal hyperplasia; BMI = body mass index; DM = diabetes mellitus; HbA 1C = glycosylated haemoglobin; HTN = hypertension; PAC = plasma aldosterone concentration; PAH = primary adrenal hyperplasia; PRA = plasma renin activity; SD = standard deviation; SLT = saline loading test
In this study, we found a 13% prevalence of PA in 100 consecutive type 2 diabetic patients with poorly controlled hypertension. All 13 patients with PA had resistant hypertension. Our findings are in keeping with the only other published study that looked at the prevalence of PA in type 2 diabetic patients with resistant hypertension; they found a similar prevalence at 14%. 23 Importantly, definitive treatment of PA in our study, with either surgical removal of the adrenal APA or blockade with an aldosterone antagonist, resulted in better BP control and a reduction in the use of antihypertensive medications.
Studies over the past decade have demonstrated a 3%-13% prevalence of PA in unselected adult hypertensive patients, with a higher prevalence in patients with more severe hypertension (table 3) . 31 In a study by Mosso et al., 32 the prevalence of PA increased with the severity of hypertension, being 2% in patients with mild hypertension, 8% in patients with moderate hypertension, and 13.2% in patients with severe hypertension. As discussed earlier, it is probable that the prevalence of PA might be higher in hypertensive type 2 diabetic patients. Indeed, the prevalence of 13% seen in our study is higher than that reported in most studies evaluating the prevalence of PA in unselected adult hypertensive patients (table  3) , [33] [34] [35] [36] [37] [38] [39] though it seems comparable to 13.2%, reported by Mosso et al. 32 amongst patients with severe hypertension. In the absence of a control group of non-diabetic hypertensive subjects, it is difficult to comment on whether the observed prevalence in our study is indeed higher than that seen in the non-diabetic hypertensive population. A previous study from Singapore, conducted in an unselected adult hypertensive population, had reported a 5% prevalence of PA. 37 In contrast, in our study, the prevalence rate was higher, at 13%. However, the higher prevalence seen in our cohort could also be explained by the fact that the patients in our cohort had more severe hypertension than in this earlier study from Singapore; three-quarters of the patients in this earlier study were taking a single antihypertensive medication, with the majority of the remaining patients taking two drugs, as opposed to all patients in our cohort having either difficult-to-control or resistant hypertension. Further studies that directly compare the prevalence of PA in diabetic vs. non-diabetic hypertensive patients are needed to confirm whether the prevalence is indeed higher amongst hypertensive type 2 diabetic patients.
In recent years, we have gathered more insights into the role of aldosterone and its potential adverse effects on the cardiovascular system, independent of its effect on BP. Patients with PA are at higher risk of stroke, myocardial infarction, atrial fibrillation and left ventricular hypertrophy than matched individuals with essential hypertension. 16 Additionally, a higher prevalence of metabolic syndrome and greater insulin resistance have been demonstrated in patients with PA. 40, 41 These metabolic abnormalities were corrected following the removal of the APA. 19, 20 Taken together with the findings of the study by Umpierrez et al., 23 our study reinforces the need to screen for PA in type 2 diabetic patients with resistant hypertension.
The major strength of our study was the systematic approach employed to follow up on positive screening PAC-to-PRA ratios. We performed a confirmatory 4-h We acknowledge several limitations of our study. The first limitation concerns the difficulty in interpreting the PAC-to-PRA ratio in patients receiving medications that interfere with the renin-angiotensin-aldosterone system. It is often not possible to safely withdraw antihypertensive medications for 2-4 weeks in patients with difficult-tocontrol or resistant hypertension. The false positive screening tests due to the use of beta blockers would have been weeded out by the use of the confirmatory 4-h intravenous 0.9% SLT. Diuretics, ACE inhibitors, and angiotensin 2 receptor blockers might have resulted in false negative PAC-to-PRA ratios; we did not perform a confirmatory 4-h intravenous 0.9% SLT in all 100 patients, and this might have led to our inability to identify these patients with a false negative PAC-to-PRA ratio, potentially leading to an underestimation of the prevalence of PA in our cohort. Also, we chose a PAC-to-PRA ratio greater than 550 pmol/L per ng/mL per h, together with a corresponding PAC greater than 415 pmol/L, to constitute a positive screening test. This might have excluded a few patients with PA who had an elevated PAC-to-PRA ratio but a corresponding PAC of less than 415 pmol/L. The other limitation, as discussed earlier, was the lack of a control group of non-diabetic hypertensive subjects. Although this does not affect the prevalence of PA noted in our study, it does not allow us to comment on whether the observed prevalence in our study is indeed higher than that seen in the nondiabetic hypertensive population. 23, 32, 42 In summary, undiagnosed PA might account for 13% of type 2 diabetic patients with resistant hypertension. Identification and treatment of this reversible cause of hypertension in type 2 diabetic patients would have a tremendous impact on achieving BP control, allowing significant reduction in long-term cardiovascular morbidity and mortality. We therefore recommend that all type 2 diabetic patients with resistant hypertension be screened for the presence of PA.
